Literature DB >> 2261484

The dissimilar interactions of the calcium antagonist flunarizine with different phospholipid classes and molecular species: a differential scanning calorimetry study.

P G Thomas1, A J Verkleij.   

Abstract

The influence of the class IV calcium antagonist flunarizine on the phase behaviour of different species of the major phospholipid classes of mammalian plasma membranes has been examined using differential scanning calorimetry. We show that it has the ability to substantially influence the phase behaviour of phospholipids. Flunarizine significantly influences the gel to liquid-crystalline transition temperature of phosphatidylserines whilst having little effect on those of the phosphatidylethanolamines tested. The liquid-crystalline to inverted hexagonal phase transition of phosphatidylethanolamines is, however, strongly induced by the presence of flunarizine. Examination of the effect of flunarizine on the phase behaviour of different phosphatidylcholine species revealed an acyl-chain dependent influence. Dissimilar results with phosphatidylcholines, phosphatidylethanolamines and phosphatidylserines reveal different locations and ionization states for the drug in the different phospholipid bilayers. These results not only indicate an essential role for the ionization state of the drug in determining drug-phospholipid interactions but also the role of the phospholipid in determining the ionization state of the drug and have important implications for drug-membrane interactions demonstrating that drug interaction with one phospholipid may bear no relation whatsoever to its interaction with another.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261484     DOI: 10.1016/0005-2736(90)90297-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Binding of the calcium antagonist flunarizine to phosphatidylcholine bilayers: charge effects and thermodynamics.

Authors:  P G Thomas; J Seelig
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

2.  Trans fatty acid derived phospholipids show increased membrane cholesterol and reduced receptor activation as compared to their cis analogs.

Authors:  Shui-Lin Niu; Drake C Mitchell; Burton J Litman
Journal:  Biochemistry       Date:  2005-03-22       Impact factor: 3.162

Review 3.  Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.

Authors:  Thomas Pietschmann
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

4.  Inhibition of mediator release in RBL-2H3 cells by some H1-antagonist derived anti-allergic drugs: relation to lipophilicity and membrane effects.

Authors:  M J Fischer; J J Paulussen; D A Horbach; E P Roelofsen; J C van Miltenburg; N J de Mol; L H Janssen
Journal:  Inflamm Res       Date:  1995-02       Impact factor: 4.575

5.  Mitolysosome exocytosis, a mitophagy-independent mitochondrial quality control in flunarizine-induced parkinsonism-like symptoms.

Authors:  Feixiang Bao; Lingyan Zhou; Rui Zhou; Qiaoying Huang; Junguo Chen; Sheng Zeng; Yi Wu; Liang Yang; Shufang Qian; Mengfei Wang; Xueying He; Shan Liang; Juntao Qi; Ge Xiang; Qi Long; Jingyi Guo; Zhongfu Ying; Yanshuang Zhou; Qiuge Zhao; Jiwei Zhang; Di Zhang; Wei Sun; Mi Gao; Hao Wu; Yifan Zhao; Jinfu Nie; Min Li; Quan Chen; Jiekai Chen; Xiao Zhang; Guangjin Pan; Hong Zhang; Mingtao Li; Mei Tian; Xingguo Liu
Journal:  Sci Adv       Date:  2022-04-13       Impact factor: 14.136

6.  Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.

Authors:  Paula M Perin; Sibylle Haid; Richard J P Brown; Juliane Doerrbecker; Kai Schulze; Carsten Zeilinger; Markus von Schaewen; Brigitte Heller; Koen Vercauteren; Eva Luxenburger; Yasmine M Baktash; Florian W R Vondran; Sietkse Speerstra; Abdullah Awadh; Furkat Mukhtarov; Luis M Schang; Andreas Kirschning; Rolf Müller; Carlos A Guzman; Lars Kaderali; Glenn Randall; Philip Meuleman; Alexander Ploss; Thomas Pietschmann
Journal:  Hepatology       Date:  2015-10-09       Impact factor: 17.425

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.